Rocket Pharmaceuticals investors face August 11, 2025 lead plaintiff deadline.

Rosen Law Firm reminds investors who purchased Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, of the August 11, 2025 lead plaintiff deadline for a class action lawsuit. Investors may be entitled to compensation without payment of fees or costs through a contingency fee arrangement. To join the lawsuit, visit https://rosenlegal.com/submit-form/?case_id=40316 or call Phillip Kim, Esq., at 866-767-3653.

Investors who purchased Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025, and May 26, 2025, are reminded of an important August 11, 2025, deadline. The Rosen Law Firm has announced that a class action lawsuit has been filed on behalf of investors who may have suffered losses due to alleged securities fraud during this period.

The lawsuit alleges that Rocket Pharmaceuticals made materially false and misleading statements about the safety and clinical trial protocol of its drug, RP-A501. Specifically, the complaint claims that the company knew about Serious Adverse Events (SAEs), including the death of participants, but did not disclose this information to shareholders. This led to artificially inflated stock prices, resulting in damages when the true details were revealed.

Investors who purchased securities during the Class Period may be entitled to compensation without paying any out-of-pocket fees or costs through a contingency fee arrangement. To join the Rocket Pharmaceuticals class action, investors should visit [https://rosenlegal.com/submit-form/?case_id=40316](https://rosenlegal.com/submit-form/?case_id=40316) or contact Phillip Kim, Esq., at 866-767-3653.

The Rosen Law Firm, with a strong track record in securities class actions, encourages investors to select qualified counsel. The firm has achieved significant settlements in the past and is ranked highly by ISS Securities Class Action Services.

Investors should act promptly, as the August 11 deadline is approaching. Failure to do so may result in missing out on potential compensation.

References:
[1] https://www.prnewswire.com/news-releases/rckt-investors-have-opportunity-to-lead-rocket-pharmaceuticals-inc-securities-fraud-lawsuit-302503563.html
[2] https://www.marketscreener.com/quote/stock/ROCKET-PHARMACEUTICALS-IN-40561561/news/RCKT-Investors-Have-Opportunity-to-Lead-Rocket-Pharmaceuticals-Inc-Securities-Fraud-Lawsuit-50496023/